Cardiol Therapeutics Inc. (CRDL)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Drug Manufacturers - Specialty & Generic
Cardiol Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | 0.9528 | 0.9528 | 0.8701 | 0.8899 | 439,337 |
| Nov 18, 2026 | 0.9878 | 0.9940 | 0.9325 | 0.9501 | 309,736 |
| Nov 17, 2026 | 0.9700 | 0.9916 | 0.9500 | 0.9718 | 347,442 |
| Nov 16, 2026 | 1.01 | 1.04 | 0.9535 | 0.9798 | 278,550 |
| Nov 13, 2026 | 1.02 | 1.04 | 0.9702 | 1.00 | 451,724 |
| Nov 12, 2026 | 1.01 | 1.07 | 0.9701 | 1.04 | 441,953 |
| Nov 11, 2026 | 1.05 | 1.07 | 1.00 | 1.01 | 514,215 |
| Nov 10, 2026 | 1.01 | 1.05 | 1.01 | 1.02 | 311,246 |
| Nov 9, 2026 | 0.9900 | 1.06 | 0.9752 | 1.03 | 406,707 |
| Nov 6, 2026 | 0.9748 | 1.00 | 0.9400 | 0.9950 | 596,746 |
| Nov 5, 2026 | 1.00 | 1.03 | 0.9150 | 0.9265 | 733,919 |
| Nov 4, 2026 | 1.05 | 1.06 | 0.9951 | 1.01 | 870,985 |
| Nov 3, 2026 | 1.05 | 1.07 | 1.03 | 1.05 | 370,813 |
| Nov 2, 2026 | 1.11 | 1.12 | 1.03 | 1.04 | 740,367 |
| Oct 30, 2026 | 1.17 | 1.17 | 1.10 | 1.11 | 711,704 |
| Oct 29, 2026 | 1.17 | 1.22 | 1.16 | 1.17 | 557,093 |
| Oct 28, 2026 | 1.16 | 1.18 | 1.13 | 1.17 | 450,622 |
| Oct 27, 2026 | 1.12 | 1.16 | 1.12 | 1.14 | 313,852 |
| Oct 26, 2026 | 1.12 | 1.15 | 1.11 | 1.12 | 580,157 |
| Oct 23, 2026 | 1.15 | 1.16 | 1.10 | 1.12 | 1,101,793 |
| Name | Shares | % | Source |
|---|---|---|---|
MMCAP International Inc. SPC · also on 13F· joint filing· may incl. warrants· filed May 2026 | 21.1M | 16.5% | 13G |
MMCAP International Inc. SPC | 15.6M | 12.2% | 13F |
Tejara Capital Ltd | 7.4M | 5.8% | 13F |
Tejara Capital Ltd · also on 13F· may incl. warrants· filed Sep 2026 | 6.4M | 5.0% | 13G |
Ikarian Capital, LLC | 3.3M | 2.6% | 13F |
AMERIPRISE FINANCIAL INC | 2.2M | 1.8% | 13F |
Woodline Partners LP | 2.2M | 1.7% | 13F |
J. Goldman & Co LP | 1.9M | 1.5% | 13F |
Point72 Asset Management, L.P. | 1.7M | 1.4% | 13F |
TWO SIGMA INVESTMENTS, LP | 1.1M | 0.9% | 13F |
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD).
Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
based on 127.69M shares outstanding
30d Avg
525.33K
60d Avg
1.04M
90d Avg
1.20M
Signal8's dilution snapshot of CRDL as of Dec 31, 2025 records an effective F-10 shelf registration (effective Sep 16, 2026), an at-the-market sales agreement dated Nov 3, 2026, 1 outstanding warrant series and a PIPE closed Jan 23, 2026, from SEC filings. Cardiol Therapeutics Inc. (NASDAQ: CRDL) traded at $0.8899 on Nov 19, 2026, down 6.34% from the previous close of $0.9501. 52-week range: $0.8701 to $2.34. The company is in the Healthcare sector (Drug Manufacturers - Specialty & Generic).